BACKGROUND: Elderly patients with stage I NSCLC who undergo surgical resection are at high risk of treatment-related toxicity. Stereotactic body radiation therapy (SBRT) may provide an alternative treatment with a favorable toxicity profile. METHODS: A population-based registry in North-Holland was used to conduct a matched-pair analysis of overall survival (OS) after surgery versus SBRT for elderly patients (age ⩾75) who were diagnosed between 2005 and 2007. Patients were matched by age, stage, gender, and treatment year; co-morbidity data was not available. SBRT was delivered at two centers; 17 centers provided surgery. RESULTS: A total of 120 patients could be matched (60 surgery, 60 SBRT). Median age was 79years, 67% were male, and 64% had T1 disease. Median follow-up was 43months. Thirty-day mortality was 8.3% after surgery and 1.7% after SBRT. OS at one- and three-years was 75% and 60% after surgery, and 87% and 42% after SBRT, respectively (log-rank p=0.22). Limiting the analysis to SBRT patients with pathological confirmation of disease and their matches revealed no significant difference between groups. CONCLUSION: Similar OS outcomes are achieved with surgery or SBRT for stage I NSCLC in elderly patients. Comorbidity data and outcomes from centralized surgical programs are needed for more robust conclusions.
BACKGROUND: Elderly patients with stage I NSCLC who undergo surgical resection are at high risk of treatment-related toxicity. Stereotactic body radiation therapy (SBRT) may provide an alternative treatment with a favorable toxicity profile. METHODS: A population-based registry in North-Holland was used to conduct a matched-pair analysis of overall survival (OS) after surgery versus SBRT for elderly patients (age ⩾75) who were diagnosed between 2005 and 2007. Patients were matched by age, stage, gender, and treatment year; co-morbidity data was not available. SBRT was delivered at two centers; 17 centers provided surgery. RESULTS: A total of 120 patients could be matched (60 surgery, 60 SBRT). Median age was 79years, 67% were male, and 64% had T1 disease. Median follow-up was 43months. Thirty-day mortality was 8.3% after surgery and 1.7% after SBRT. OS at one- and three-years was 75% and 60% after surgery, and 87% and 42% after SBRT, respectively (log-rank p=0.22). Limiting the analysis to SBRT patients with pathological confirmation of disease and their matches revealed no significant difference between groups. CONCLUSION: Similar OS outcomes are achieved with surgery or SBRT for stage I NSCLC in elderly patients. Comorbidity data and outcomes from centralized surgical programs are needed for more robust conclusions.
Authors: Peng Wang; Dong Zhang; Xue-Guang Guo; Bao-Jun Sun; Xiang-Qun Fang; Ge-Ping Qu; Chang-Ting Liu Journal: Nan Fang Yi Ke Da Xue Xue Bao Date: 2017-07-20
Authors: Y Tajima; H Nakayama; T Itonaga; S Shiraishi; M Okubo; R Mikami; S Sugahara; K Tokuuye Journal: Br J Radiol Date: 2015-05-21 Impact factor: 3.039
Authors: Shervin M Shirvani; Jing Jiang; Daniel R Gomez; Joe Y Chang; Thomas A Buchholz; Benjamin D Smith Journal: Lung Cancer Date: 2013-08-21 Impact factor: 5.705
Authors: Christopher Cao; Daniel Wang; Caroline Chung; David Tian; Andreas Rimner; James Huang; David R Jones Journal: J Thorac Cardiovasc Surg Date: 2018-09-15 Impact factor: 5.209